<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article         dtd-version="1.4">
            <front>

                <journal-meta>
                                                                <journal-id>sdü tıp fak derg</journal-id>
            <journal-title-group>
                                                                                    <journal-title>Medical Journal of Süleyman Demirel University</journal-title>
            </journal-title-group>
                                        <issn pub-type="epub">2602-2109</issn>
                                                                                            <publisher>
                    <publisher-name>Süleyman Demirel Üniversitesi</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id/>
                                                                                                                                                                                            <title-group>
                                                                                                                        <trans-title-group xml:lang="tr">
                                    <trans-title>Romatoid Artritli Hastalarda Anti–Siklik Sitrülinize Peptit ( Anti-CCP) Antikorunun ve IL-6 Seviyelerinin Klinik Aktiviteyle İlişkisi</trans-title>
                                </trans-title-group>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                <name>
                                    <surname>Ugan</surname>
                                    <given-names>Yunus</given-names>
                                </name>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Kutlucan</surname>
                                    <given-names>Ali</given-names>
                                </name>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Turan</surname>
                                    <given-names>Orkan</given-names>
                                </name>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Şahin</surname>
                                    <given-names>Mehmet</given-names>
                                </name>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Tunç</surname>
                                    <given-names>Ercan</given-names>
                                </name>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Taş</surname>
                                    <given-names>Tekin</given-names>
                                </name>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20120930">
                    <day>09</day>
                    <month>30</month>
                    <year>2012</year>
                </pub-date>
                                        <volume>19</volume>
                                        <issue>3</issue>
                                        <fpage>87</fpage>
                                        <lpage>91</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20110614">
                        <day>06</day>
                        <month>14</month>
                        <year>2011</year>
                    </date>
                                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 1994, Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi</copyright-statement>
                    <copyright-year>1994</copyright-year>
                    <copyright-holder>Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi</copyright-holder>
                </permissions>
            
                                                                                                <trans-abstract xml:lang="tr">
                            <p>Amaç: Süleyman Demirel Üniversitesi Tıp Fakültesi (SDUTF) Romatoloji Polikliniğine başvuran romatoid artrit (RA)&#039;li hastalarda anti–siklik sitrülinize peptit (Anti-CCP) antikorunun ve IL-6 seviyelerinin klinik aktiviteyle ilişkisinin araştırılması amaçlanmıştır. Gereç-Yöntem: Çalışmamıza SDUTF Romatoloji ünitesinde ayaktan ya da yatarak takip edilen Amerikan Romatoloji Derneği (ACR) kriterlerini dolduran çoğunluğu klinik olarak aktif 30 RA hastası (E/K; 3/27) ile 22 sağlıklı kontrol (E/K; 2/20) ve Avrupa Spondiloartropati Çalışma Grubu (ESSG) kriterlerini dolduran 29 Ankilozan Spondilit (AS)&#039;li hasta (E/K; 4/25) da hasta kontrol grubu olarak alınmıştır. Çalışmamızda klinik aktivite göstergesi olarak IL-6, ESR, CRP ve RA&#039;li hastalar için DAS 28 modifiye hastalık aktivitesi AS&#039;li hastalar için de Bath Ankilozan Spondilit Hastalık Aktivite İndeksi (BASDAI) kullanılmıştır. Bulgular: Tüm RA&#039;li olgular değerlendirildiğinde anti-CCP antikor pozitifliği ile DAS 28 skoru arasında anlamlı bir korelasyon bulunmadı (r = 0.172, p = 0.364). DAS 28 skoru ile CRP arasında oldukça anlamlı bir ilişki (r = 0.525, p = 0.006) varken, IL-6 değerleri arasında anlamlı bir ilişki saptanmadı (r = 0.09, p = 0.629). RA&#039;li hasta grubunda anti-CCP antikoru ile CRP arasında (r = 0.399, p = 0.029) ve anti-CCP ile ESH arasında (r = 0.490, p= 0.006) orta derecede pozitif korelasyonlar bulunmasına rağmen IL-6 ile yoktu (r = 0.146, p= 0.440). Ancak anti-CCP antikor titresiyle IL-6 düzeyleri kıyaslandığında anlamlı bir korelasyon saptandı ( r =0.462, p=0,01). Sonuç: RA&#039;li hastalarda anti-CCP antikorları ve IL-6 seviyeleri ile klinik aktivasyon arasında bir ilişki saptanmamıştır. Ancak anti-CCP antikor titresiyle IL-6 düzeyleri arasında pozitif bir korelasyon saptanmış ve bunun klinik öneminin araştırılması için daha geniş kapsamlı çalışmalara ihtiyaç olduğunu düşünmekteyiz.</p></trans-abstract>
                                                            
            
                                                    
                                                <kwd-group xml:lang="tr">
                                                    <kwd>Romatoid Artrit</kwd>
                                                    <kwd>   DAS 28</kwd>
                                                    <kwd>   Anti-CCP</kwd>
                                                    <kwd>   Ýnterlökin 6</kwd>
                                            </kwd-group>
                                                                                                            </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">Zvaifler NJ: Etiology and Pathogenesis of Rheumatoid Arthritis: Arthritis and Allied Conditions. McCarty DJ, Kopman WJ. (eds). Lea and Febiger, Pennsylvania 1993; 723-36.</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">Wildler RL. Rheumatoid Arthritis, Epidemiology, Pathology and Pathogenesis. In: Schumacher RH, eds. Primer on the Rheumatic Disease. Arthiritis Foundation, 1993; 86-89.</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">Harris ED. Etiology and Pathogenesis of Rheumatoid Arthritis. In Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. WB Saunders 1993; 833-73.</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">Hochberg MC. Adult and Juvenile Rheumatoid Arthiritis: current epidemiologic concepts. Epidemiology Rev 1981; 3: 27-44.</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">Akkoç N, Akar S. Romatoid artrit epidemiyolojisi. Turkiye Klinikleri J Int Med Sci 2006; 2: 1-6.</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">Wolheim FA. The clinical features of rheumatoid arthritis. European Journal of Radiology 1998; 27: 1824.</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">Harris ED. Clinical Features of Rheumatoid Arthritis. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, eds. Textbook of Rheumatology. 1993; 874-11.</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">Harris ED. Rheumatoid Arthritis: Pathophysiology and implications for therapy. N Engl J Med 1990; 332: 1277-89.</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">Mc Grego AJ, Silman AJ. Classification and Epidemiology. Klippel JH, Dieppe PS (eds). Mosby, London 1998; 5: 1-6.</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">Yoshizaki K, Nishimoto N, Mihara M. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with humanized anti-IL-6 receptor antibody. Springer Seminar Immunopathol. 1998; 20: 24759.</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">Cronstein BN. Interleukin-6: A key mediator of systemic and local symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007; 65: 11-5.</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">Cutolo M, Seriolo B, Accardo S. Androgens in Rheumatoid Arthritis. Rheumatology in Europe. 1995; 1: 211-14.</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">Prevoo ML, van &#039;t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">Balsa A, Carmona L, González-Álvaro I, Belmonte MA, Tina X, Sanmartí R. Value of DAS-28 and DAS 28-3 as compared to ACR-defined remission in rheumatoid arthritis. J Rheumatol 2004; 31: 40-6.</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">Akkoc Y, Karatepe AG, Akar S, Kirazli Y, Akkoc N. A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. Rheumatol Int 2005; 25: 280-4.</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">Lundberg K, Nijenhuis S, Vossenaar ER, Palmblad K, van Venrooij WJ, et al. 17) Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during three years in early rheumatoid arthritis (the TIRA project). Ann Rheum Dis 2004; 63: 1085-89.</mixed-citation>
                    </ref>
                                    <ref id="ref17">
                        <label>17</label>
                        <mixed-citation publication-type="journal">Us D, Gülmez D, Hasçelik G. . Mikrobiyol Bul. 2003; 37: 163-70.</mixed-citation>
                    </ref>
                                    <ref id="ref18">
                        <label>18</label>
                        <mixed-citation publication-type="journal">Kamali S, Polat NG, Kasapoglu E, Gul A, Ocal L, et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren&#039;s syndrome, and Wegener&#039;s granulomatosis. 2005; 24: 673-6.</mixed-citation>
                    </ref>
                                    <ref id="ref19">
                        <label>19</label>
                        <mixed-citation publication-type="journal">De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman I E A, et al. Annals of the rheumatic diseases 2005; 64: 299-302.</mixed-citation>
                    </ref>
                                    <ref id="ref20">
                        <label>20</label>
                        <mixed-citation publication-type="journal">Correa PA, Tobon GJ, Citera G, Cadena J, Schneeberger E, et al. Anti cyclic citrullinated antibodies in rheumatoid arthritis: relation with clinical features, cytokines and HLA-DRB1. Biomedica 2004; 24:140- 52.</mixed-citation>
                    </ref>
                                    <ref id="ref21">
                        <label>21</label>
                        <mixed-citation publication-type="journal">Alexiou I, Germenis A, Koutroumpas A, Kontogianni A, Theodoridou K, Sakkas LI. Clin Rheumatol. 2008; 27: 511-3.</mixed-citation>
                    </ref>
                                    <ref id="ref22">
                        <label>22</label>
                        <mixed-citation publication-type="journal">Aridoðan BC, Kaya S, Savaþ S, Cetin ES, Akkuþ S, Demirci M. The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis. 2008 ; 42: 669-74.</mixed-citation>
                    </ref>
                                    <ref id="ref23">
                        <label>23</label>
                        <mixed-citation publication-type="journal">A. Shingada, V. Chewoolkar &amp; L. Bichile : Assessment of disease activity in Rheumatoid Arthritis using urinary CTx-I levels as a marker of bone destruction and serum IL-6 as a marker of inflammation.. The Internet Journal of Rheumatology. 2009; 6: 1.</mixed-citation>
                    </ref>
                                    <ref id="ref24">
                        <label>24</label>
                        <mixed-citation publication-type="journal">J Avouac, L Gossec, M Dougados. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006; 65: 845-51.</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
